WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006079474) PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/079474    International Application No.:    PCT/EP2006/000431
Publication Date: 03.08.2006 International Filing Date: 19.01.2006
IPC:
A61K 31/00 (2006.01), A61K 31/5377 (2006.01), A61P 7/02 (2006.01), A61P 9/10 (2006.01)
Applicants: BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE) (For All Designated States Except US).
MISSELWITZ, Frank [DE/DE]; (DE) (For US Only).
KUBITZA, Dagmar [DE/DE]; (DE) (For US Only).
PARK, Son-Mi [DE/DE]; (DE) (For US Only).
WEHLING, Klaus [DE/DE]; (DE) (For US Only)
Inventors: MISSELWITZ, Frank; (DE).
KUBITZA, Dagmar; (DE).
PARK, Son-Mi; (DE).
WEHLING, Klaus; (DE)
Common
Representative:
BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE)
Priority Data:
05001893.6 31.01.2005 EP
Title (EN) PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS
(FR) PREVENTION ET TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES
Abstract: front page image
(EN)The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
(FR)La présente invention concerne le domaine de la coagulation sanguine, plus spécifiquement, une méthode de traitement d'un trouble thromboembolique par une seule administration quotidienne à un patient le nécessitant d'un inhibiteur du facteur Xa direct sous forme posologique orale, ledit inhibiteur du facteur Xa possédant une demi-durée de vie de concentration de plasma indiquant un intervalle d'administration de deux ou trois fois par jour, par ex. de dix heures tout au plus.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)